Keytruda

Partner Content

Immuno-Oncology Conference Kandeepan Ganeshalingam

Partner Content

Updates on Keytruda and future potential therapies advanceme...

SMi Group reports on preparations for SMi's inaugural Immuno-Oncology Conference, which is scheduled to take place 26 - 27 September in London.

News

Medical vials and Syringe, Isolated on Blue background

Moderna and Merck expand partnership to develop new cancer v...

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines.

News

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

Firms will co-develop Lenvima and Keytruda combinations

News

Its Herceptin biosimilar nearing launch, Celltrion begins wo...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda.

News

Keytruda not enough to lift Merck - so will it turn to M&A?

Merck & Co.

News

Keytruda approved for bladder cancer in Europe, first to pro...

Merck Sharp & Dohme’s Keytruda has been approved in Europe for metastatic urothelial carcinoma, a move which helps it catch up with its immunotherapy rivals.

Updates on Keytruda and future potential therapies advanceme...

Moderna and Merck expand partnership to develop new cancer v...

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

Its Herceptin biosimilar nearing launch, Celltrion begins wo...

Keytruda not enough to lift Merck - so will it turn to M&A?

Keytruda approved for bladder cancer in Europe, first to pro...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Keytruda

Editor's Picks